The Cortland Acres community offers a variety of housing choices to meet the needs of active older adults.
Celestiallabs Inc. is a Hoffman Estates, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Two things distinguish CHIA in our pursuit of improving the Massachusetts health care system: our public-interest perspective, and our unique data sets. Our perspective is rooted in our independence – our agenda and findings are not colored by the special interests of industry or politics – and in the talents and commitment of CHIA employees. CHIA`s mission is to be the agency of record for Massachusetts health care information, to responsibly steward sensitive and confidential data, and to objectively report reliable and meaningful information about the quality, affordability, utilization, access, and outcomes of the Massachusetts health care system. We pursue this mission in the public interest. This informs our objective perspective, and our commitment to serving a broad, diverse audience. We are a hub, connecting our products to policymakers, public and private payers and providers, employers, researchers, and the residents of Massachusetts. Our vision is a transparent health care system where reliable information provides common ground for improvement and empowers people and organizations to make informed decisions.
Seagrove Inc. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.